|
Abstract:
|
Roux-en-Y gastric bypass (RYGB) surgery leads to approximately 40% reduction in body weight and achieves amelioration of T2DM in over 80% of the patients. RYGB also dramatically improves a myriad of other obesity-related comorbidities such as fatty liver disease, hypertension, and cardiovascular diseases. Thus, unraveling the mechanisms by which RYGB elicits therapeutic benefits could potentially lead to the development of effective obesity and diabetes medications. We developed deepath, a generic method for pathway enrichment analysis, which utilizes multi-omics data to identify important biological functions with significant evidence. We applied deepath on proteomics and metabolomics data and identified metabolic and signaling pathways that RYGB dysregulates.
|
